# An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

> **NCT03606577** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03606577
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-30
- **Primary completion:** 2022-02-08
- **Final completion:** 2027-11-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606577, "An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03606577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*